NasdaqGS - Delayed Quote USD

Lifecore Biomedical, Inc. (LFCR)

5.99 -0.13 (-2.12%)
At close: May 15 at 4:00 PM EDT
Loading Chart for LFCR
DELL
  • Previous Close 6.12
  • Open 6.08
  • Bid 5.96 x 400
  • Ask 6.02 x 300
  • Day's Range 5.89 - 6.14
  • 52 Week Range 4.50 - 11.46
  • Volume 235,486
  • Avg. Volume 200,667
  • Market Cap (intraday) 182.976M
  • Beta (5Y Monthly) 0.98
  • PE Ratio (TTM) --
  • EPS (TTM) -2.14
  • Earnings Date May 16, 2024 - May 19, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 8.00

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

www.lifecore.com

459

Full Time Employees

May 28

Fiscal Year Ends

Recent News: LFCR

Performance Overview: LFCR

Trailing total returns as of 5/15/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

LFCR
3.23%
S&P 500
11.29%

1-Year Return

LFCR
39.30%
S&P 500
28.71%

3-Year Return

LFCR
50.78%
S&P 500
27.18%

5-Year Return

LFCR
40.10%
S&P 500
87.28%

Compare To: LFCR

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LFCR

Valuation Measures

Annual
As of 5/15/2024
  • Market Cap

    182.98M

  • Enterprise Value

    276.51M

  • Trailing P/E

    --

  • Forward P/E

    10.33

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.74

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    2.68

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -96.41%

  • Return on Assets (ttm)

    -4.67%

  • Return on Equity (ttm)

    -104.52%

  • Revenue (ttm)

    103.27M

  • Net Income Avi to Common (ttm)

    -64.24M

  • Diluted EPS (ttm)

    -2.14

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    19.09M

  • Total Debt/Equity (mrq)

    505.94%

  • Levered Free Cash Flow (ttm)

    15.96M

Research Analysis: LFCR

Company Insights: LFCR

Research Reports: LFCR

People Also Watch